n(6)-carboxymethyllysine has been researched along with Macular Degeneration in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, S; Cui, JZ; Fang, E; Kojic, L; Kurji, K; Law, G; Lin, T; Matsubara, JA; Prasad, SS; Walker, GB; White, V | 1 |
| Cotch, MF; Eiríksdottir, G; Ferrucci, L; Gudnason, V; Harris, TB; Jonasson, F; Klein, R; Schaumberg, DA; Semba, RD; Sun, K | 1 |
| Gustienė, O; Stanislovaitienė, D; Steponavičiūtė, R; Žaliūnas, R; Žaliūnienė, D; Žemaitienė, R | 1 |
| Crabb, JW; Gu, J; Gu, X; Nagaraj, RH; Ni, J; Yuan, X; Yue, X | 1 |
| Hagino, N; Ishihara, A; Kikuchi, M; Kobayashi, S; Nagai, R; Nishioka, T; Nomura, M | 1 |
| Hangai, M; Hinton, DR; Horiuchi, S; Ishibashi, T; Lopez, PF; Murata, T; Nagai, R; Ryan, SJ | 1 |
| Alt, A; Bretzel, RG; Clausen, JT; Hammes, HP; Hoerauf, H; Laqua, H; Schleicher, E | 1 |
7 other study(ies) available for n(6)-carboxymethyllysine and Macular Degeneration
| Article | Year |
|---|---|
Parainflammation associated with advanced glycation endproduct stimulation of RPE in vitro: implications for age-related degenerative diseases of the eye.
Topics: Cell Survival; Cells, Cultured; Chemokine CXCL11; Down-Regulation; Gene Expression Profiling; Gene Expression Regulation; Glycation End Products, Advanced; Humans; Inflammation; Keratins; Lysine; Macular Degeneration; Pigment Epithelium of Eye; Postmortem Changes; Reproducibility of Results; Retinal Drusen; Serum Albumin, Bovine; Tissue Donors; Up-Regulation | 2013 |
Serum carboxymethyllysine, an advanced glycation end product, and age-related macular degeneration: the Age, Gene/Environment Susceptibility-Reykjavik Study.
Topics: Age Factors; Aged; Aged, 80 and over; Cross-Sectional Studies; Disease Susceptibility; Enzyme-Linked Immunosorbent Assay; Female; Gene-Environment Interaction; Glycation End Products, Advanced; Humans; Iceland; Logistic Models; Lysine; Macular Degeneration; Male; Prevalence; Risk Factors; Visual Acuity | 2014 |
N-carboxymethyllysine as a biomarker for coronary artery disease and age-related macular degeneration.
Topics: Aged; Aging; Biomarkers; Body Mass Index; Case-Control Studies; Coronary Angiography; Coronary Artery Disease; Early Diagnosis; Enzyme-Linked Immunosorbent Assay; Female; Humans; Lipoproteins; Lysine; Macular Degeneration; Male; Middle Aged; Oxidative Stress; Prevalence; Risk Factors | 2016 |
Plasma protein pentosidine and carboxymethyllysine, biomarkers for age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Arginine; Autoantibodies; Biomarkers; Blood Proteins; Case-Control Studies; Chromatography, Liquid; Female; Fluorometry; Humans; Logistic Models; Lysine; Macular Degeneration; Male; Mass Spectrometry; Middle Aged; Pyrroles | 2009 |
Overproduction of N(epsilon)-(carboxymethyl)lysine-induced neovascularization in cultured choroidal explant of aged rat.
Topics: Age Factors; Aging; Animals; Antibodies; Capillaries; Choroid; Choroidal Neovascularization; Glycation End Products, Advanced; Lysine; Macular Degeneration; Male; Organ Culture Techniques; Platelet-Derived Growth Factor; Rats; Rats, Wistar; Time Factors; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2007 |
Advanced glycation end products in age-related macular degeneration.
Topics: Adult; Aged; Aged, 80 and over; Choroidal Neovascularization; Glycation End Products, Advanced; Humans; Immunoenzyme Techniques; Keratins; Lysine; Macular Degeneration; Pigment Epithelium of Eye | 1998 |
N(epsilon)(carboxymethyl)lysin and the AGE receptor RAGE colocalize in age-related macular degeneration.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Epiretinal Membrane; Female; Glycation End Products, Advanced; Humans; Immunoenzyme Techniques; Lysine; Macular Degeneration; Male; Membrane Proteins; NF-kappa B; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Retinal Neovascularization | 1999 |